Shaily Engineering Plastics declares Q4FY22 result: IP acquired for Pen Injector Contract for pen injector finalised with leading Indian Pharma company Highest ever revenues recorded in FY22 This has been on the back of improved traction seen across segments and ramp up in projects. The visibility we have across various businesses gives immense confidence that we will be able to scale up further and grow Revenue growth has been aided by growth in business across verticals especially the Healthcare & Toy segment; we have added new SKUs in Home Furnishing segment and Devices Result PDF
Conference Call with Shaily Engineering Plastics Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.